Dermata Therapeutics, Inc. Common Stock (DRMA) is a publicly traded Healthcare sector company. As of October 15, 2026, DRMA trades at $0.90 with a market cap of $4.26M and a P/E ratio of -0.14. DRMA moved +39.80% today. Year to date, DRMA is -69.57%; over the trailing twelve months it is -84.24%. Its 52-week range spans $0.60 to $23.70. Analyst consensus is buy with an average price target of $4.00. Rallies surfaces DRMA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for DRMA, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $0.90 |
| Market Cap | $4.26M |
| P/E Ratio | -0.14 |
| EPS | $-8.16 |
| Dividend Yield | 0.00% |
| 52-Week High | $23.70 |
| 52-Week Low | $0.60 |
| Volume | 97.39M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-7.56M |
| Gross Margin | 0.00% |
1 analysts cover DRMA: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $4.00.